7:15 PM
 | 
Jul 07, 2009
 |  BC Extra  |  Company News

India's IPAB rejects Gleevec patent application

India's Intellectual Property Appellate Board (IPAB) ruled against granting a patent for cancer drug Gleevec imatinib from Novartis AG (NYSE:NVS; SIX:NOVN). Upholding a 2006 decision by the Indian Controller of Patents and Designs,...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >